‘A Missed Therapeutic Opportunity? SGLT-2 Inhibitor Use in General Medicine Patients With Heart Failure: A Retrospective Audit of Admissions to a Tertiary Health Service’
Objective: Sodium-glucose co-transporter-2 inhibitors (SGLT2-I’s) are novel oral hypoglycaemic agents, with proven decreased MACE and re-hospitalisation risk in type 2 diabetic patients with concomitant heart failure. This study aimed to assess the current practice in the use of SGLT2-I’s in general...
Main Authors: | Padeepa Perera, Ronan O’Donnabhain, Timothy Fazio, Douglas Johnson, Peter Lange |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-10-01
|
Series: | Clinical Medicine Insights: Cardiology |
Online Access: | https://doi.org/10.1177/11795468221133607 |
Similar Items
-
An Audit Of Hospital Admission Of Leprosy Cases In A Tertiary Care Center
by: Srinivasulu K N, et al.
Published: (2003-01-01) -
A national audit of SGLT2 use in England
by: McGovern, A, et al.
Published: (2017) -
SGLT2-Inhibitors and Euglycemia Diabetic Ketoacidosis: A Missed Diagnosis
by: Muhammad Nadeem Ahmed Khan, et al.
Published: (2023-12-01) -
MDGs a missed opportunity?
Published: (2015-05-01) -
Copenhagen : a missed opportunity
by: Sadhavi Sharma
Published: (2011)